Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Every week, patients become eligible for the Shingles National Immunisation Programme

Why wait? Take action to help protect your patients from shingles as soon as they become eligible

Vaccine uptake in eligible cohorts in England (data from UK Health Security Agency)

Severely immunocompromised patients aged ≥ 50 years

25.4%

of eligible severely immunocompromised patients who turned 50 and over from 1st Sep 2024 to 31st Aug 2025 had received their first dose by 23rd Oct 20251

Immunocompetent 65-year-olds

26.6%

of adults who turned 65 between 1st Sep 2024 and 31st Aug 2025 had received their first dose by 23rd Oct 20251

Immunocompetent 70-year-olds

37.4%

of adults who turned 70 between 1st Sep 2024 and 31st Aug 2025 had received their first dose by 23rd Oct 20251

Since 1st September 2025, eligibility for shingles vaccination expanded to severely immunocompromised individuals aged 18 years and over with no upper age limit (as defined in the Green Book)2,3

Eligibility in England & Wales2,3

NA

The eligible cohorts for the Shingles National Immunisation Programme in England & Wales are:

  • Individuals aged ≥ 18 years who are severely immunocompromised (as defined in the Green Book)
    • There is no upper age limit for this cohort
  • Individuals who turned 65 on or after 1st September 2023
    • Those born before 1st September 1958 will become eligible when they turn 70
    • Remain eligible until their 80th birthday
  • Individuals aged 70-79 years
    • Remain eligible until their 80th birthday

Eligibility in Northern Ireland & Scotland4-6

NA

The eligible cohorts for the Shingles National Immunisation Programme in Northern Ireland & Scotland are:

  • Individuals aged ≥ 18 years who are severely immunocompromised (as defined in the Green Book)
    • There is no upper age limit for this cohort
  • Individuals aged 65 or 70 years on 1st September 2025
    • Remain eligible until their 80th birthday
    • This includes individuals that have already become eligible for the shingles vaccine due to their age (i.e. already 65 or 70 on the 1st September 2023 or 2024) and have not yet been vaccinated
    • Those born before 2nd September 1957, will become eligible when they are aged 70 (on 1st September)
  • Implementation of the Programme is expected to reduce the burden of shingles for your patients and practice
    • In September 2013, the Shingles National Immunisation Programme was introduced into the routine schedule for adults aged 70 years with a phased catch-up programme for 71-79 years.7
    • In the first 5 years (when a live shingles vaccine was used), there were 40,500 fewer GP consultations and 1,840 fewer hospitalisations for shingles and post-herpetic neuralgia in England.7
  • The shingles vaccination attracts quality and outcomes framework (QOF) points in England. A maximum of 10 points are awarded if at least 60% of your patients who turned 80 years old in the preceding 12 months, received a shingles vaccine between the ages of 70 and 79 years, in line with the Shingles National Immunisation Programme.
    • Receive an item of service fee per dose of shingles vaccination administered in line with national guidance8

Visit illuminate for free, peer-led and practical resources

Visit illuminate to access helpful resources and tools designed to support the implementation of the Shingles National Immunisation Programme in your practice. This is a GSK-owned and funded website, containing promotional information.

NA

References:

  1. UK Health Security Agency. Shingrix vaccine uptake report(adults eligible from September 2023 to August 2024 and vaccinated to the end of October 2024): England. Updated 31 July 2025.
  2. UKHSA Green Book: Shingles(herpes zoster): the green book chapter
  3. UK Health Security Agency. Shingles vaccination programme: expansion of vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over. Published July 2025.
  4. Shingles Immunisation Eligible groups – Public Health Scotland.
  5. Shingles Vaccination Programme 2025-26 SGHD CMO (2025) Chief Medical Officer for Scotland.
  6. Department of Health Northern Ireland. Shingles Vaccination Programme 2025/26. Published August 2025.
  7. Andrews N, Stowe J, Kuyumdzhieva G, et al., BMJ Open 1-15.
  8. NHS England. Quality and Outcomes Framework Guidance for 2025/26. Published April 2024. Available at: https://www.england.nhs.uk/wp- content/uploads/2025/03/quality-outcomes-framework-guidance-for-2025-26.pdf. UK Health Security Agency: Introduction of Shingrix vaccine for the whole programme and expansion of eligible cohorts letter. Published July 2023.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

May 2026 | PM-GB-SGX-WCNT-230025 (V6.0)